THE BioMed Co., Ltd. (KOSDAQ:214610)

South Korea flag South Korea · Delayed Price · Currency is KRW
5,370.00
-80.00 (-1.47%)
At close: Jun 27, 2025, 3:30 PM KST
-62.26%
Market Cap 27.65B
Revenue (ttm) 4.59B
Net Income (ttm) -27.71B
Shares Out 5.15M
EPS (ttm) -6,082.23
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 52,536
Average Volume 176,163
Open 5,400.00
Previous Close 5,450.00
Day's Range 5,270.00 - 5,650.00
52-Week Range 4,360.00 - 33,100.00
Beta 0.60
RSI 43.98
Earnings Date Aug 14, 2025

About THE BioMed

THE BioMed Co., Ltd. provides point-of-care-testing diagnostic systems based on Lab-on-a-Chip technology. The company offers molecular diagnostics devices comprising Veri-Q PREP M16 (G2-16TU) system, a device that include membrane to extract nucleic acid using tube; VERI-Q PCR 316, a device to get the result in a short time using plastic chip; VERI-Q PCR 204 (G2-4), a device to deliver the real-time PCR system; PCR and sample prep kits; Veri-Q PCR 316 PB products; and LabChip, sample tube, and pre-filtering column products. It also provides bio... [Read more]

Industry Electromedical and Electrotherapeutic Apparatus
Founded 2009
Employees 50
Stock Exchange KOSDAQ
Ticker Symbol 214610
Full Company Profile

Financial Performance

In 2024, THE BioMed's revenue was 4.64 billion, a decrease of -13.55% compared to the previous year's 5.37 billion. Losses were -30.85 billion, 19.7% more than in 2023.

Financial Statements

News

There is no news available yet.